Market Cap 116.51B
Revenue (ttm) 11.02B
Net Income (ttm) -535.60M
EPS (ttm) N/A
PE Ratio 30.07
Forward PE 28.71
Profit Margin -4.86%
Debt to Equity Ratio 0.00
Volume 310,200
Avg Vol 1,419,764
Day's Range N/A - N/A
Shares Out 253.72M
Stochastic %K 93%
Beta 0.32
Analysts Strong Sell
Price Target $494.52

Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 341 6100
Address:
50 Northern Avenue, Boston, United States
Carmenfean
Carmenfean Dec. 24 at 5:03 PM
0 · Reply
PiPips
PiPips Dec. 24 at 4:02 PM
$VRTX Future valuation dynamics revolve around the pace at which operating leverage materializes relative to expectations, with outcomes shaped by timing and discipline. Missteps risk prolonged valuation stagnation.
0 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker Dec. 24 at 3:42 PM
$KYTX all big players in the cell therapy space like $AZN $GILD $AMGN $VRTX will have noticed these life changing results and have their M&A analysts running the numbers up and down right now to evaluate next steps in 2026. A merry Christmas to everyone here. Let's do some good with our investments here on this holy day 🎄🎅💲 https://kyvernatx.com/education-events/educational-videos/
0 · Reply
svertical1
svertical1 Dec. 22 at 8:57 PM
$VRTX $480 looking reasonable short term!
0 · Reply
orphaschwiesow
orphaschwiesow Dec. 21 at 6:38 AM
Biotech Outlook 2026 | Bank of America • BofA sees small- and mid-cap biotech well positioned into 2026 • Top picks: $ARGX Argenx • $KALV KalVista Pharmaceuticals • $OCUL Ocular Therapeutix • $VRTX Vertex Pharmaceuticals • Key drivers: clearer regulatory pathways, improved commercial execution, and a dense slate of upcoming clinical data
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Dec. 19 at 4:32 PM
$LXRX $VRTX had the SHITTIEST Topline results for their Journavx. Stock tanked like a rock, in December. ONLY for ACUTE PAIN. Pilavapadin? ADDRESSES THE GOLDEN EGG LEVEL OF PAIN. ONLY TO GET FDA APPROVAL FOLLOWING MONTH. LOL. : Gemini / Google explains it well: "Vertex's drug (Suzetrigine/Journavx) is for acute pain, while Pilavapadin targets chronic neuropathic pain, specifically Diabetic Peripheral Neuropathic Pain (DPNP), acting on a different pathway (AAK1) for nerve pain, not immediate injury pain. So, yes, Pilavapadin addresses a "higher level" (chronic, nerve-related) pain condition, distinct from the acute, short-term pain Vertex's drug handles, making them different classes for different pain types. " SO YEAH, TRUMPS HATE, ERGO, THE ADMIN'S 'HATE' FOR ADDICTION CAUSING THERAPIES, PLUS THE MASSIVELY HIGHER LEVEL OF PAIN CONTROL PILAVAPADIN HAS OVERALL VS ACUTE PAIN, MAKES IT A SURE SHOT. TOPLINE FOR PILAVAPADIN HAD IT'S CRY BABIES. BUT LOOKING AT IT FROM A MACRO VIEW =WIN.
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 3:22 PM
$VRTX is currently positioned at $447.38, with an RSI of 57.6 indicating bullish momentum but not overbought. The stock is above its 30-day moving average (MA30) of 435.67 and 50-day moving average (MA50) of 428.71, suggesting a positive trend. The 60-day high of 463.85 presents a potential resistance level, while the low of 374.17 provides a solid support base. Actionable Trade Alert: - Suggested Entry: $448 - Stop Loss: $430 (approximately 4% risk) - Take Profit Targets: 1. $460 (2.67% gain) 2. $475 (6.18% gain) 3. $525 (17.3% gain) This trade plan capitalizes on the current upward momentum, with the potential for a significant return at the third target. Monitor the trade closely, especially around the 60D high. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 2:09 AM
Actionable Trade Alert for $VRTX: Market Context: $VRTX closed at $457.72, approaching its 60D high of $463.85. The RSI at 66.53 indicates bullish momentum but is nearing overbought territory. The 30-day moving average (MA30) at 434.12 and the 50-day moving average (MA50) at 427.09 suggest a strong upward trend. Directional Bias: Given the proximity to the 60D high and the positive trend indicated by the MAs, we maintain a bullish bias. However, caution is warranted due to the RSI suggesting potential overbought conditions. Trade Plan: - Suggested Entry: $457.72 - Stop Loss: $440.00 (approximately 3.9% below entry) - Take Profit Targets: 1. $465.00 (1.6% gain) 2. $475.00 (3.8% gain) 3. $537.00 (17.3% gain) Monitor market conditions closely, especially around the high. Consider adjusting stop loss to lock in profits as targets are reached. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
stockrandd
stockrandd Dec. 16 at 10:14 PM
$MRNA $VRTX $DHR $TNXP Have you heard about $BHST Are you Bullish? https://www.youtube.com/watch?v=VCRFmrw7nhQ
0 · Reply
Jax1on_Pollard
Jax1on_Pollard Dec. 16 at 4:43 PM
$VRTX SBFM this is how life-changer names start… ignored, cheap, growing 🔥
0 · Reply
Latest News on VRTX
Committee stocks on the move: Uber and Vertex Pharma

Nov 4, 2025, 1:22 PM EST - 7 weeks ago

Committee stocks on the move: Uber and Vertex Pharma

UBER


Columbia Balanced Fund Q3 2025 Portfolio Update

Nov 4, 2025, 2:30 AM EST - 7 weeks ago

Columbia Balanced Fund Q3 2025 Portfolio Update

EA EBAY ELV INTU TEL


Vertex Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 4:02 PM EST - 7 weeks ago

Vertex Reports Third Quarter 2025 Financial Results


Vertex Pharmaceuticals Remains A Buy Heading Into Q3 Earnings

Oct 28, 2025, 11:59 AM EDT - 2 months ago

Vertex Pharmaceuticals Remains A Buy Heading Into Q3 Earnings


Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR

Oct 2, 2025, 1:31 PM EDT - 2 months ago

Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR

IJR NOW


Vertex Announces Key Advancements Across Kidney Portfolio

Sep 25, 2025, 7:45 AM EDT - 3 months ago

Vertex Announces Key Advancements Across Kidney Portfolio


Calls of the Day: Abbvie, Vertex, Veeva and Vistra

Sep 8, 2025, 1:47 PM EDT - 3 months ago

Calls of the Day: Abbvie, Vertex, Veeva and Vistra

ABBV VEEV VST


Vertex to Participate in Upcoming September Investor Conferences

Aug 20, 2025, 4:00 PM EDT - 4 months ago

Vertex to Participate in Upcoming September Investor Conferences


Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet

Aug 12, 2025, 2:34 PM EDT - 4 months ago

Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet


Weakness In Vertex Stock Seen As Buying Opportunity

Aug 5, 2025, 2:05 PM EDT - 5 months ago

Weakness In Vertex Stock Seen As Buying Opportunity


Carmenfean
Carmenfean Dec. 24 at 5:03 PM
0 · Reply
PiPips
PiPips Dec. 24 at 4:02 PM
$VRTX Future valuation dynamics revolve around the pace at which operating leverage materializes relative to expectations, with outcomes shaped by timing and discipline. Missteps risk prolonged valuation stagnation.
0 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker Dec. 24 at 3:42 PM
$KYTX all big players in the cell therapy space like $AZN $GILD $AMGN $VRTX will have noticed these life changing results and have their M&A analysts running the numbers up and down right now to evaluate next steps in 2026. A merry Christmas to everyone here. Let's do some good with our investments here on this holy day 🎄🎅💲 https://kyvernatx.com/education-events/educational-videos/
0 · Reply
svertical1
svertical1 Dec. 22 at 8:57 PM
$VRTX $480 looking reasonable short term!
0 · Reply
orphaschwiesow
orphaschwiesow Dec. 21 at 6:38 AM
Biotech Outlook 2026 | Bank of America • BofA sees small- and mid-cap biotech well positioned into 2026 • Top picks: $ARGX Argenx • $KALV KalVista Pharmaceuticals • $OCUL Ocular Therapeutix • $VRTX Vertex Pharmaceuticals • Key drivers: clearer regulatory pathways, improved commercial execution, and a dense slate of upcoming clinical data
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Dec. 19 at 4:32 PM
$LXRX $VRTX had the SHITTIEST Topline results for their Journavx. Stock tanked like a rock, in December. ONLY for ACUTE PAIN. Pilavapadin? ADDRESSES THE GOLDEN EGG LEVEL OF PAIN. ONLY TO GET FDA APPROVAL FOLLOWING MONTH. LOL. : Gemini / Google explains it well: "Vertex's drug (Suzetrigine/Journavx) is for acute pain, while Pilavapadin targets chronic neuropathic pain, specifically Diabetic Peripheral Neuropathic Pain (DPNP), acting on a different pathway (AAK1) for nerve pain, not immediate injury pain. So, yes, Pilavapadin addresses a "higher level" (chronic, nerve-related) pain condition, distinct from the acute, short-term pain Vertex's drug handles, making them different classes for different pain types. " SO YEAH, TRUMPS HATE, ERGO, THE ADMIN'S 'HATE' FOR ADDICTION CAUSING THERAPIES, PLUS THE MASSIVELY HIGHER LEVEL OF PAIN CONTROL PILAVAPADIN HAS OVERALL VS ACUTE PAIN, MAKES IT A SURE SHOT. TOPLINE FOR PILAVAPADIN HAD IT'S CRY BABIES. BUT LOOKING AT IT FROM A MACRO VIEW =WIN.
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 3:22 PM
$VRTX is currently positioned at $447.38, with an RSI of 57.6 indicating bullish momentum but not overbought. The stock is above its 30-day moving average (MA30) of 435.67 and 50-day moving average (MA50) of 428.71, suggesting a positive trend. The 60-day high of 463.85 presents a potential resistance level, while the low of 374.17 provides a solid support base. Actionable Trade Alert: - Suggested Entry: $448 - Stop Loss: $430 (approximately 4% risk) - Take Profit Targets: 1. $460 (2.67% gain) 2. $475 (6.18% gain) 3. $525 (17.3% gain) This trade plan capitalizes on the current upward momentum, with the potential for a significant return at the third target. Monitor the trade closely, especially around the 60D high. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 2:09 AM
Actionable Trade Alert for $VRTX: Market Context: $VRTX closed at $457.72, approaching its 60D high of $463.85. The RSI at 66.53 indicates bullish momentum but is nearing overbought territory. The 30-day moving average (MA30) at 434.12 and the 50-day moving average (MA50) at 427.09 suggest a strong upward trend. Directional Bias: Given the proximity to the 60D high and the positive trend indicated by the MAs, we maintain a bullish bias. However, caution is warranted due to the RSI suggesting potential overbought conditions. Trade Plan: - Suggested Entry: $457.72 - Stop Loss: $440.00 (approximately 3.9% below entry) - Take Profit Targets: 1. $465.00 (1.6% gain) 2. $475.00 (3.8% gain) 3. $537.00 (17.3% gain) Monitor market conditions closely, especially around the high. Consider adjusting stop loss to lock in profits as targets are reached. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
stockrandd
stockrandd Dec. 16 at 10:14 PM
$MRNA $VRTX $DHR $TNXP Have you heard about $BHST Are you Bullish? https://www.youtube.com/watch?v=VCRFmrw7nhQ
0 · Reply
Jax1on_Pollard
Jax1on_Pollard Dec. 16 at 4:43 PM
$VRTX SBFM this is how life-changer names start… ignored, cheap, growing 🔥
0 · Reply
AAUS1
AAUS1 Dec. 16 at 1:00 PM
$VRTX Regular buyer on dips 💪
0 · Reply
svertical1
svertical1 Dec. 16 at 2:57 AM
$VRTX Think about how these FDA Policy changes affect Vertex Pipeline Approvals, significantly accelerating approvals as these will now be included or considered (Real World Experience/Data, One Trial, Plausible ‘testable’ mode of action, Vouchers, US Manufacturing, Wealthy Nation Pricing). Most of which should benefit Vertex! Vertex should immediately file BLA for all drugs meeting these criteria…..which includes ALL P2 drugs! Should also go for label expansion based on ‘mode of action’ and ‘real world data’!
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 5:43 AM
Actionable Trade Alert for $VRTX: Market Context: $VRTX is currently showing bullish momentum with a last close of $452.04. The RSI at 62.76 indicates that the stock is nearing overbought territory, but still has room for upward movement. The 30-day moving average (MA30) at 432.93 and the 50-day moving average (MA50) at 425.93 support a bullish trend, reinforcing the potential for further gains. Directional Bias: Given the current price is above both MAs and approaching the 60D high of 463.85, there is a strong bullish bias. The price action within the 60D range (374.17 - 463.85) suggests a potential breakout. Trade Plan: - Suggested Entry: $455.00 - Stop Loss: $440.00 (3.3% below entry) - Take Profit Targets: 1. $465.00 (2.2% gain) 2. $475.00 (4.4% gain) 3. $530.00 (16.9% gain) This plan aims for a minimum of 17% ROI on the third target, aligning with current market conditions. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Dec. 15 at 2:47 AM
$VRTX rolling into 2026 this will print to a $500 stock
1 · Reply
lextrading
lextrading Dec. 13 at 4:25 AM
$VRTX The stock has climbed about 25% since I pointed out its strong historical support after a 20% drop in August. It’s now breaking out, pushing past its resistance trendline from ATHs. https://lextrading.beehiiv.com/p/vertex-victory-lap
1 · Reply
svertical1
svertical1 Dec. 12 at 3:45 PM
$VRTX Nice setup for significant breakout!
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 10:35 PM
Actionable Trade Alert for $VRTX: Market Context: $VRTX is currently trading at $444.71, showing strong momentum with an RSI of 61.64, indicating bullish sentiment but nearing overbought territory. The stock is above both the 30-day MA (431.82) and the 50-day MA (425.04), reinforcing a positive trend. Directional Bias: The stock's recent performance is favorable, with the 60-day high at $463.85 providing a key resistance level. The current price is significantly above the 60-day low of $374.17, suggesting a bullish outlook. Trade Plan: - Suggested Entry: $444.71 - Take Profit Targets: 1. TP1: $455.00 (2.3% gain) 2. TP2: $470.00 (5.7% gain) 3. TP3: $520.00 (17% gain) - Stop Loss: $430.00 (3.3% risk) This plan offers a favorable risk-reward ratio with potential for over 17% ROI on TP3. Monitor market conditions closely for any changes. https://privateprofiteers.com
0 · Reply
Quantumup
Quantumup Dec. 11 at 3:25 PM
Truist⬆️ $FULC's PT to $18-reiterated at a Buy and said, 'Positive Reception Permeates Around Pociredir, Deserving of Greater Valuation Credit Post Cohort 4 $CRSP - $VRTX PFE $AGIO $NVO NVS EMMS Truist went on to say: Positive reception is persisting around the cohort 4 data from the ph.Ib PIONEER study for pociredir in SCD which came in as a win for FULC, with robust efficacy shown in the way of the abs. HbF bar of 20% being hit in ~58% of patients, showing a clear dose-response over Cohort 3b's ~44% of patients. A rapid treatment delta, and supportive safety profile serve as additional support. We remain encouraged by the developmental, regulatory, and competitive prospects of pociredir, and believe this milestone justifies the greater enthusiasm and confidence towards the program's potential. We increase our PT to $18 (from $14) and reiterate our Buy rating on FULC shares.
0 · Reply
JarvisFlow
JarvisFlow Dec. 10 at 8:09 PM
Wells Fargo updates rating for Vertex Pharmaceuticals ( $VRTX ) to Overweight, target set at 460 → 515.
0 · Reply
IN0V8
IN0V8 Dec. 10 at 4:54 PM
$VRTX Buy Wells Fargo raises PT to $515 from $460
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 2:39 AM
Actionable Trade Alert for $VRTX: Market Context: $VRTX is currently trading at $437.01, showing a neutral RSI of 50.71, indicating no strong momentum. The stock is above both the 30-day MA of 430.16 and the 50-day MA of 423.17, suggesting a bullish bias in the short term. Directional Bias: The price is closer to the 60-day high of 463.85, indicating potential upward movement. The ATR of 12.03 suggests moderate volatility, providing room for price fluctuations. Trade Plan: - Suggested Entry: $440.00 (above current close to confirm upward momentum) - Stop Loss: $425.00 (below the 50-day MA for risk management) - Take Profit Targets: 1. $450.00 (2.27% ROI) 2. $460.00 (4.55% ROI) 3. $512.00 (17.1% ROI) With the potential for a significant upside, this trade offers a favorable risk-reward ratio. Monitor price action closely and adjust stops as needed. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
peterpancake
peterpancake Dec. 9 at 7:03 PM
$VRTX If you want a really really good Christmas you need to buy APLT right now....that's applied therapeutics. buy it
0 · Reply